United Therapeutics Corporation (UTHR): A Cheap Biotech Stock to Invest In Now
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...
United Therapeutics price target lowered to $460 from $475 at UBS
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
Arquitos Capital Management Q4 2024 Commentary
Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500. Click here to read the full ...
United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
United Therapeutics president Michael Benkowitz sells shares worth $3.65m
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...
Business Wire22d
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
“At this year’s annual congress, we are delighted to share further findings that support long-term outcomes and dosing of Tyvaso DPI, as well as interim data from our PHINDER study that is ...